Flotufolastat (18F)

A radiopharmaceutical used in PET imaging

{{Drugbox | verifiedfields = changed | verifiedrevid = 123456789 | IUPAC_name = (2S)-2-[[4-[[(2S)-2-(3-fluoropropyl)cyclohexyl]carbonyl]amino]butanoyl]-N-[(1S)-1-(carboxymethyl)-2-oxo-2-[[4-(trifluoromethyl)phenyl]methyl]ethyl]pyrrolidine-1-carboxamide | image = Flotufolastat_F-18_gallium.svg | image2 = | tradename = | legal_status = | routes_of_administration = Intravenous | ATC_prefix = | ATC_suffix = | CAS_number = | PubChem = | DrugBank = | UNII = | KEGG = | ChEMBL = | synonyms = }}

Flotufolastat (18F) is a radiopharmaceutical used in positron emission tomography (PET) imaging. It is specifically designed for the detection of prostate cancer by targeting the prostate-specific membrane antigen (PSMA), a protein highly expressed in prostate cancer cells.

Mechanism of Action

Flotufolastat (18F) functions by binding to PSMA, which is overexpressed on the surface of prostate cancer cells. The radiolabeled compound emits positrons, which are detected by PET scanners to produce detailed images of the cancerous tissues. This allows for precise localization and staging of prostate cancer, aiding in diagnosis and treatment planning.

Synthesis and Radiolabeling

The synthesis of Flotufolastat (18F) involves the incorporation of the radioactive isotope fluorine-18 into a PSMA-targeting ligand. The process requires careful handling and specialized equipment to ensure the stability and purity of the radiopharmaceutical. The radiolabeling is typically performed in a cyclotron, where fluorine-18 is produced and then chemically attached to the targeting molecule.

Clinical Applications

Flotufolastat (18F) is primarily used in the imaging of prostate cancer. It provides high-resolution images that help in the detection of both primary and metastatic lesions. This radiopharmaceutical is particularly useful in cases where conventional imaging techniques are inconclusive. It is also used to monitor the response to therapy and to detect recurrence of the disease.

Safety and Efficacy

The use of Flotufolastat (18F) in clinical settings has been shown to be both safe and effective. The radiation dose from the radiopharmaceutical is relatively low, and adverse reactions are rare. The efficacy of Flotufolastat (18F) in detecting prostate cancer lesions has been demonstrated in several clinical studies, showing superior sensitivity and specificity compared to other imaging modalities.

Regulatory Status

Flotufolastat (18F) has been approved for use in several countries for the imaging of prostate cancer. Its approval is based on clinical trials that have demonstrated its safety and effectiveness in detecting PSMA-expressing tumors.

Related pages

• Prostate cancer
• Positron emission tomography
• Radiopharmaceutical
• Prostate-specific membrane antigen